DNPUF - Myovant Sciences cancels Q2 earnings call in light of Sumitovant acquisition
- Myovant Sciences ( NYSE: MYOV ) has cancelled its Q2 earnings call , scheduled for Oct. 26, due to the buyout of the women's health company by Sumitovant Biopharma.
- Earlier Monday, Sumitovant, a unit of Sumitovo Pharma ( OTCPK:DNPUF ), said it would acquire the the remaining 48% stake in Myovant which it currently does not own for $1.7B and take it private.
- See what Seeking Alpha contributor BioSci Capital Partners had to say about Myovant ( MYOV ) recently after the company rejected an earlier bid from Sumitovant .
For further details see:
Myovant Sciences cancels Q2 earnings call in light of Sumitovant acquisition